Assessment of AI Program 'DRISTi' as a Screening Tool
Part of paid clinical trials in Oxford, North Carolina.
- Sponsor
- Artelus AI
- Study ID
- NCT07222293
- Status
- Recruiting
Conditions
- Diabetic Retinopathy (DR)
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Fundus Image Grading — DIAGNOSTIC_TESTThe image is graded by a fully automated AI device
Study Details
A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in the outcomes thus proving DRISTi is an effective DR diagnosis tool.
Key Dates
- Start date
- Nov 23, 2025
- Status verified
- Dec 2025
- Primary completion
- Mar 31, 2026
- Completion
- Mar 31, 2026
Study Design
- Enrollment
- 900 participants (estimated)
Primary Outcome Measure
Accuracy of AI Grade [ Time Frame: From time of arrival to completion of diagnostic tests, up to 8 hours ]
Central Contacts
- Jeanne Champion, Primary Site Coordinator Oxford9192347003
- Adriana Valencia, Site Coordinator Raleigh9192347406
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| New Century Ophthalmology - Oxford | Oxford | North Carolina | 27565 | Vinod Jindal, MD (PRINCIPAL_INVESTIGATOR) |
| New Century Ophthalmology - Raleigh | Raleigh | North Carolina | 27617 | Sumeet Jindal, MD (SUB_INVESTIGATOR) Vinod Jindal, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Oxford, NC
Related Studies
- Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)Recruiting · University of Illinois at Chicago · Chicago, Illinois
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPHASE4 · Enrolling By Invitation · Harrow Inc · Tyler, Texas
- Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma CenterRecruiting · University of California, San Francisco · San Francisco, California